neoag
Neoantigen × AI
Daily research signal
№52Brief2026-10-17

Intismeran autogene plus Keytruda shows five-year melanoma benefit

Today's brief is dominated by the intismeran autogene (mRNA-4157/V940) plus Keytruda story on two fronts: new 5-year Phase IIb melanoma data presented at ASCO and Merck's CEO signaling that the six-week personalized manufacturing cycle should compress over time.AIM at Melanoma FoundationCNBC

Moderna's 10% pullback shows how much of the sector's valuation now rides on this program ahead of a critical readout later this month.24/7 Wall St. Separately, Dana-Farber's NeoVax points to the modality expanding beyond melanoma into ovarian cancer.AllSci

3new stories1 in context
ClinicalyesterdayNew

Dana-Farber’s personalized cancer vaccine NeoVax shows immune activity in ovarian cancer trial - AllSci

Dana-Farber's personalized cancer vaccine NeoVax showed immune activity in an ovarian cancer trial, per the report. The item provides headline-level detail only, but the signal matters because it extends the personalized vaccine approach beyond melanoma, where today's clinical activity is concentrated, into ovarian cancer. Full data disclosure will be needed to judge whether immune activity translates into clinical benefit.

MelanomaOvarian cancer
news · yesterday · AllSci

Also new today02

01
CommercialyesterdayNew

Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put - 24/7 Wall St.

Moderna fell 10% to $214.03 in morning trading as profit taking hit a steep run tied to its personalized cancer vaccine, while BioNTech slipped 2% to $88.59 and Pfizer edged up 0.3% to $29.54; the iShares Biotechnology ETF fell 2% against a roughly flat S&P 500. The pullback follows August news that intismeran autogene plus Keytruda met its primary endpoint in a late-stage melanoma trial, which had driven Moderna's best single-day gain. With a critical trial readout due later this month, the move underscores how concentrated the vaccine thesis has become in near-term catalysts.

MelanomaModernaBioNTech
news · yesterday · 24/7 Wall St.
02
Commercial3 days agoNew

Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make - CNBC

Merck CEO Rob Davis told CNBC he expects the personalized cancer vaccine being developed with Moderna to become faster to manufacture over time, though the near-term focus is making sure supply and the market are ready for launch. The current turnaround spans roughly six weeks from sequencing a patient's tumor to hospital delivery, a cycle driven by the vaccine's design targeting each patient's specific tumor mutations rather than a one-size-fits-all approach, paired with Keytruda. Manufacturing cycle time is a direct lever on how many patients the partnership can reach and on the economics of the program.

ModernaMerck
news · 3 days ago · CNBC

Catching up01

Relevant work from earlier we're still surfacing — not today's news.

Explore the field

TopicsTrialsLearn